JP2007511529A5 - - Google Patents

Download PDF

Info

Publication number
JP2007511529A5
JP2007511529A5 JP2006539927A JP2006539927A JP2007511529A5 JP 2007511529 A5 JP2007511529 A5 JP 2007511529A5 JP 2006539927 A JP2006539927 A JP 2006539927A JP 2006539927 A JP2006539927 A JP 2006539927A JP 2007511529 A5 JP2007511529 A5 JP 2007511529A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
antibody
dosage form
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006539927A
Other languages
English (en)
Japanese (ja)
Other versions
JP5027512B2 (ja
JP2007511529A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/037910 external-priority patent/WO2005048935A2/en
Publication of JP2007511529A publication Critical patent/JP2007511529A/ja
Publication of JP2007511529A5 publication Critical patent/JP2007511529A5/ja
Application granted granted Critical
Publication of JP5027512B2 publication Critical patent/JP5027512B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2006539927A 2003-11-14 2004-11-12 免疫調節法 Expired - Fee Related JP5027512B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US52014803P 2003-11-14 2003-11-14
US60/520,148 2003-11-14
US56774104P 2004-05-03 2004-05-03
US60/567,741 2004-05-03
PCT/US2004/037910 WO2005048935A2 (en) 2003-11-14 2004-11-12 Methods of modulating immunity

Publications (3)

Publication Number Publication Date
JP2007511529A JP2007511529A (ja) 2007-05-10
JP2007511529A5 true JP2007511529A5 (cg-RX-API-DMAC7.html) 2007-12-27
JP5027512B2 JP5027512B2 (ja) 2012-09-19

Family

ID=34623123

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006539927A Expired - Fee Related JP5027512B2 (ja) 2003-11-14 2004-11-12 免疫調節法

Country Status (9)

Country Link
US (3) US7883703B2 (cg-RX-API-DMAC7.html)
EP (2) EP2397189B1 (cg-RX-API-DMAC7.html)
JP (1) JP5027512B2 (cg-RX-API-DMAC7.html)
AU (1) AU2004291107B2 (cg-RX-API-DMAC7.html)
CA (1) CA2545806C (cg-RX-API-DMAC7.html)
DK (1) DK1687066T3 (cg-RX-API-DMAC7.html)
ES (1) ES2393674T3 (cg-RX-API-DMAC7.html)
PL (1) PL1687066T3 (cg-RX-API-DMAC7.html)
WO (1) WO2005048935A2 (cg-RX-API-DMAC7.html)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030108548A1 (en) * 1993-06-01 2003-06-12 Bluestone Jeffrey A. Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US7883703B2 (en) 2003-11-14 2011-02-08 The Brigham And Women's Hospital, Inc. Methods of modulating immunity
SG188175A1 (en) 2004-06-03 2013-03-28 Novimmune Sa Anti-cd3 antibodies and methods of use thereof
US8663634B2 (en) * 2005-07-11 2014-03-04 Macrogenics, Inc. Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
US20090258001A1 (en) * 2006-06-06 2009-10-15 Paul Ponath Administration of anti-CD3 antibodies in the treatment of autoimmune diseases
JP2009544761A (ja) * 2006-06-14 2009-12-17 マクロジェニクス,インコーポレーテッド 低毒性免疫抑制モノクローナル抗体を用いて自己免疫疾患を治療する方法
CA2667613A1 (en) * 2006-10-26 2008-06-05 Wisconsin Alumni Research Foundation Methods for reducing phosphate absorption
JP2010509235A (ja) * 2006-11-03 2010-03-25 ノースウェスタン ユニバーシティ 多発性硬化症の治療
CA2673470A1 (en) * 2006-12-21 2008-07-03 Macrogenics, Inc. Methods for the treatment of lada and other adult-onset autoimmune diabetes using immunosuppressive monoclonal antibodies with reduced toxicity
US20090131329A1 (en) * 2007-09-14 2009-05-21 Edmund John Miller Treatment for allograft rejection
US20110200617A1 (en) * 2008-01-18 2011-08-18 Yaron Ilan Combination therapy of beta-glycolipids and antibodies for the treatment of immune-related disorders
CA2718381A1 (en) * 2008-03-13 2009-09-17 Immuron Limited Colostrum-derived immunoglobulin preparation comprising anti-insulin antibodies for the treatment of metabolic syndrome
CA2791975C (en) * 2010-02-04 2021-02-09 The Trustees Of The University Of Pennsylvania Icos critically regulates the expansion and function of inflammatory human th17 cells
BR112012027531A2 (pt) * 2010-04-29 2017-08-08 Hadasit Medical Res Service And Development Co Ltd método de tratamento e/ou prevenção de progresso e/ou atraso de desenvolvimento de hepatite em um indivíduo, uso de uma molécula imunológica anti-cd3 e composição farmacêutica
WO2012162067A2 (en) 2011-05-21 2012-11-29 Macrogenics, Inc. Cd3-binding molecules capable of binding to human and non-human cd3
EP2714094B1 (en) 2011-06-02 2016-02-24 The University of Louisville Research Foundation, Inc. Anti-nucleolin agent-conjugated nanoparticles
WO2013022091A1 (ja) * 2011-08-11 2013-02-14 小野薬品工業株式会社 Pd-1アゴニストからなる自己免疫疾患治療剤
JP2015091761A (ja) * 2012-02-23 2015-05-14 国立大学法人大阪大学 中枢神経の損傷を治療するための組成物およびその利用
US20150132289A1 (en) * 2012-02-29 2015-05-14 Therapix Biosciences Ltd. Methods and compositions for treating psc (primary sclerosing cholangitis) or pbc (primary biliary cirrhosis) with anti-cd3 immune molecule therapy
EP2892924B1 (en) 2012-06-14 2020-11-25 Therapix Biosciences Ltd. Humanized antibodies to cluster of differentiation 3 (cd3)
KR101941004B1 (ko) * 2013-03-25 2019-01-23 주식회사 엘지화학 조절 t 세포로의 분화 유도 및 증식 촉진을 통한 면역 반응 억제용 약학 조성물
HK1251488A1 (zh) 2015-05-05 2019-02-01 The University Of Louisville Research Foundation, Inc. 作为放射致敏剂以及mri和/或x光造影剂的结合纳米粒子的抗核仁素剂
EP3504241B1 (en) * 2016-08-29 2024-05-15 Tiziana Life Sciences PLC Anti-cd3 antibody formulations
TWI849895B (zh) 2018-02-09 2024-07-21 日商小野藥品工業股份有限公司 雙特異性抗體
MX2020012598A (es) 2018-05-24 2021-05-27 Janssen Biotech Inc Agentes aglutinantes del psma y usos de estos.
DE102018213030A1 (de) 2018-08-03 2020-02-06 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Behandlung von Immunerkrankungen durch die antikörpervermittelte Neutralisierung spezifischer Darmbakterien
AR118720A1 (es) 2019-04-19 2021-10-27 Janssen Biotech Inc Métodos para tratar el cáncer de próstata con un anticuerpo anti-psma / cd3
JP7137696B2 (ja) 2019-05-14 2022-09-14 プロヴェンション・バイオ・インコーポレイテッド 1型糖尿病を予防するための方法および組成物
KR20230092863A (ko) 2020-06-11 2023-06-26 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
US20230227555A1 (en) * 2020-07-30 2023-07-20 Tiziana Life Sciences Plc Cd-3 antibodies for the treatment of coronavirus
MX2023008909A (es) 2021-01-28 2023-10-23 Janssen Biotech Inc Proteínas de unión a psma y usos de estas.
US20220332822A1 (en) * 2021-04-16 2022-10-20 Tiziana Life Sciences Plc Subcutaneous administration of antibodies for the treatment of disease
MX2023013851A (es) 2021-05-24 2023-12-08 Provention Bio Inc Metodos para el tratamiento de diabetes tipo 1.
WO2023174925A1 (en) 2022-03-14 2023-09-21 Novimmune Sa Bispecific gpc3xcd28 and gpc3xcd3 antibodies and their combination for targeted killing of gpc3 positive malignant cells

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4654210A (en) * 1979-04-26 1987-03-31 Ortho Pharmaceutical Corporation Methods and compositions using complement fixing monoclonal antibody to human T cells
US4515893A (en) * 1979-04-26 1985-05-07 Ortho Pharmaceutical Corporation Hybrid cell line for producing complement-fixing monoclonal antibody to human T cells
US4361549A (en) 1979-04-26 1982-11-30 Ortho Pharmaceutical Corporation Complement-fixing monoclonal antibody to human T cells, and methods of preparing same
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4978745A (en) 1987-11-23 1990-12-18 Centocor, Inc. Immunoreactive heterochain antibodies
US4975369A (en) 1988-04-21 1990-12-04 Eli Lilly And Company Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen
CA1339256C (en) 1989-01-26 1997-08-12 Wulf Droge Treatment of diseases associated with hiv-infections
DE69032484D1 (de) * 1989-10-27 1998-08-20 Arch Dev Corp Zusammensetzungen und deren verwendung zur förderung der immunopotentiation
US6406696B1 (en) 1989-10-27 2002-06-18 Tolerance Therapeutics, Inc. Methods of stimulating the immune system with anti-CD3 antibodies
IE922437A1 (en) * 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
NZ243706A (en) 1991-07-25 1994-08-26 Idec Pharma Corp Recombinant monkey antibodies, pharmaceutical compositions
US5756096A (en) * 1991-07-25 1998-05-26 Idec Pharmaceuticals Corporation Recombinant antibodies for human therapy
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5556763A (en) * 1992-04-06 1996-09-17 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Evaluation and treatment of patients with progressive immunosuppression
US6491916B1 (en) 1994-06-01 2002-12-10 Tolerance Therapeutics, Inc. Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies
AU6983594A (en) * 1993-06-28 1995-01-17 Lion Corporation Composition for oral cavity
US6090380A (en) * 1994-01-12 2000-07-18 Research Corporation Technologies, Inc. Treatment of rheumatoid arthritis by oral administration of pooled human immunoglobulin
US6030613A (en) * 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US5834597A (en) * 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
WO1998014209A1 (en) * 1996-10-02 1998-04-09 Ovimmune, Inc. Oral administration of chicken yolk antibodies to treat disease
WO1998047531A2 (en) * 1997-04-21 1998-10-29 Arch Development Corporation Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial tcr signal and induce clonal anergy
US6007821A (en) 1997-10-16 1999-12-28 Fordham University Method and compositions for the treatment of autoimmune disease using heat shock proteins
US7041289B1 (en) * 1997-12-05 2006-05-09 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method for treating established spontaneous auto-immune diseases in mammals
EP1171161A1 (en) 1999-04-19 2002-01-16 Richard Weisbart Treatment of adult rheumatoid arthritis by oral administration of pooled human immunoglobulin and an antacid
US6197328B1 (en) * 1999-08-20 2001-03-06 Dott Research Laboratory Nasally administrable compositions
US6346247B1 (en) * 1999-10-28 2002-02-12 Promega Corporation Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies
AUPQ431299A0 (en) * 1999-11-26 1999-12-23 Unisearch Limited Method of inducing immune tolerance
GB0001710D0 (en) * 2000-01-25 2000-03-15 Pharma Pacific Pty Ltd Therapeutic treatment
WO2001094419A2 (en) 2000-06-07 2001-12-13 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Method to induce the th1 immune response
NZ526871A (en) * 2001-01-25 2006-01-27 Bristol Myers Squibb Co Pharmaceutical dosage forms of epothilones for oral administration
AU2002327338A1 (en) 2001-07-25 2003-02-17 New York University Use of glycosylceramides as adjuvants for vaccines against infections and cancer
GB2380127A (en) * 2001-09-26 2003-04-02 Isis Innovation Treatment of chronic joint inflammation
US20030094173A1 (en) * 2001-11-14 2003-05-22 Inhale Therapeutic Systems, Inc. Aerosolization device with improved endpiece connection
JP2005517025A (ja) 2002-02-08 2005-06-09 エクサイト セラピーズ, インコーポレイテッド 免疫学的欠損を有する患者において免疫応答性を回復するための、組成物および方法
CA2475388A1 (en) 2002-02-14 2003-08-21 William J. Rutter Chimeric molecules for cleavage in a treated host
CA2479212A1 (en) * 2002-03-15 2003-09-25 Brigham And Women's Hospital, Inc. Central airway administration for systemic delivery of therapeutics
US20040253237A1 (en) * 2002-12-05 2004-12-16 Ian Walters Methods of treatment of ulcerative colitis with anti-CD3 antibodies
US20050042664A1 (en) * 2003-08-22 2005-02-24 Medimmune, Inc. Humanization of antibodies
US7883703B2 (en) * 2003-11-14 2011-02-08 The Brigham And Women's Hospital, Inc. Methods of modulating immunity
IL172175A0 (en) * 2005-11-24 2011-08-01 Hadasit Med Res Service Beta glycolipids as immuno-modulators
US20110200617A1 (en) 2008-01-18 2011-08-18 Yaron Ilan Combination therapy of beta-glycolipids and antibodies for the treatment of immune-related disorders

Similar Documents

Publication Publication Date Title
JP5828614B2 (ja) ジアルキルフマレート含有薬剤調合物
AU2006345512A1 (en) Controlled-release formulation
KR20130036217A (ko) 라퀴니모드를 이용한 루푸스 관절염의 치료
JP2020522560A5 (cg-RX-API-DMAC7.html)
CN105338970A (zh) 包含他达拉非和坦洛新的药物胶囊复合制剂
CN108283643A (zh) 一种噻嗪二酮类化合物在制备预防或治疗类风湿性关节炎的药物中的应用
CA3134145A1 (en) Methods of treating negative symptoms of schizophrenia using deuterated dextromethorphan and quinidine
CN104546841A (zh) 一种含有托匹司他的复方缓释制剂
CN101296696A (zh) 一种用于治疗痛风的药物组合物及其制备方法和用途
CN1427728A (zh) 胃排空能力测定用制剂
JP2013060427A (ja) ロキソプロフェン及びペパーミント抽出物を含有する頻尿治療用組成物
JP6523328B2 (ja) タンニン酸シタグリプチン複合体
CN119350175A (zh) 一类新型酰基苯丙氨酸衍生物、其制备方法及其作为药物的用途
RU2015109933A (ru) Композиции, включающие антитело и камостат мезилат (см)
CN1414847A (zh) 含吡喹酮的缓释抗蠕虫组合物
WO2004069246A1 (fr) Compositions pour medicament renfermant des inhibiteurs de cholinesterase en vue du traitement de la demence senile
CN102145004A (zh) 己酮可可碱在制备预防或治疗功能性便秘的药物中的用途
TW201408293A (zh) (r)-苯基披喇瑟盪於治療疾病相關疲勞之用途
CN103040807A (zh) 去-o-甲基毛狄泼老素在制备治疗高血压药物中的应用
CN102846571A (zh) 一种埃索美拉唑镁微型片剂
CN100551369C (zh) 一种含有西洛他唑的缓释制剂及其制备方法
CN1439371A (zh) 苦参素缓释剂及其制备工艺
JP2026510895A (ja) 経口バイオアベイラビリティを向上させるための医薬組成物
CN103285188B (zh) 一种益气补肾活血的中药组合物及其制备方法
CN105902694A (zh) 一种辅助冠心病术后恢复的药物组合物